AD
Adagene Inc.
ADAG · NASDAQ
$3.20 +0.16% (+$0.01)
1M -8.83%
Market Cap $120.5M
P/E Ratio -
Div. Yield -
ROE 30.65%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
30 /100
Expensive P/B 3.41x
P/S 15.71x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 24.79%
Rev. growth 6.19%
FCF growth N/A
Profitability
20 /100
Weak Net margin 229.56%
Op. margin 279.48%
FCF margin 204.34%
Quality
1 /100
Poor ROE 30.65%
ROA 22.50%
Asset turnover 0.10x
Debt
69 /100
Low Current ratio 3.07x
Int. coverage -37.67x
Debt/Equity 0.18x
Stability
24 /100
Unstable Rev. volatility 4,235.99%
EPS volatility 81.81%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ADAG
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Peter Luo
Employees
128
Headquarters
Suzhou
Upcoming events
31 MAR
Earnings
Upcoming earnings report